Citation: | Chinese Society of Cardiology, Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Chinese Expert Consensus on the Diagnosis and Treatment of Adult Fabry Disease Cardiomyopathy[J]. Journal of Rare Diseases, 2024, 3(3): 335-344. DOI: 10.3760/cma.j.cn112148-20231008-00263 |
Fabry disease (FD) is an X-linked genetic disorder caused by mutations in the GLA gene. It leads to reduced or complete deficiency of the activity of α-galactosidase A (α-Gal A), resulting in an accumulation of the metabolic substrate globotriaosylceramide (Gb3) and its derivative, globotriaosylsphingosine (Lyso-Gb3), in a wide range of cells and tissues, which causes multiple organ pathologies. In the cardiovascular system, FD predominantly leads to left ventricular hypertrophy and/or conduction abnormalities known as FD cardiomyopathy. Since FD cardiomyopathy is the leading cause of death in adult patients with FD, early diagnosis combining cardiac imaging, enzyme and substrate activity, genetic testing, and tissue biopsy, as well as early specific enzyme replacement therapy are important to improve patient prognosis. This consensus comprehen-sively summarizes the published evidence related to the diagnosis and treatment of FD cardiomyopathy at home and abroad, and provides a basis for the diagnosis and management of FD cardiomyopathy.
[1] |
中国法布雷病专家协作组. 中国法布雷病诊疗专家共识(2021年版)[J]. 中华内科杂志, 2021, 60(4): 321-330.
|
[2] |
Pieroni M, Moon JC, Arbustini E, et al. Cardiac involvement in Fabry disease: JACC review topic of the week[J]. J Am Coll Cardiol, 2021, 77(7): 922-936. doi: 10.1016/j.jacc.2020.12.024
|
[3] |
Nordin S, Kozor R, Medina-Menacho K, et al. Proposed stages of myocardial phenotype development in Fabry disease[J]. JACC Cardiovasc Imaging, 2019, 12(8 Pt 2): 1673-1683.
|
[4] |
Patel V, O'Mahony C, Hughes D, et al. Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease[J]. Heart, 2015, 101(12): 961-966. doi: 10.1136/heartjnl-2014-306782
|
[5] |
Yim J, Yau O, Yeung DF, et al. Fabry cardiomyopathy: current practice and future directions[J]. Cells, 2021, 10(6): 1532. doi: 10.3390/cells10061532
|
[6] |
Patel MR, Cecchi F, Cizmarik M, et al. Cardiovascular events in patients with Fabry disease natural history data from the fabry registry[J]. J Am Coll Cardiol, 2011, 57(9): 1093-1099. doi: 10.1016/j.jacc.2010.11.018
|
[7] |
O'Mahony C, Elliott P. Anderson-Fabry disease and the heart[J]. Prog Cardiovasc Dis, 2010, 52(4): 326-335. doi: 10.1016/j.pcad.2009.11.002
|
[8] |
Xiao Y, Sun Y, Tian T, et al. Prevalence and clinical characteristics of Fabry disease in Chinese patients with hypertrophic cardiomyopathy[J]. Am J Med Sci, 2021, 362(3): 260-267. doi: 10.1016/j.amjms.2021.01.009
|
[9] |
Doheny D, Srinivasan R, Pagant S, et al. Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017[J]. J Med Genet, 2018, 55(4): 261-268. doi: 10.1136/jmedgenet-2017-105080
|
[10] |
Nowicki M, Bazan-Socha S, Błażejewska-Hyzorek B, et al. Enzyme replacement therapy in Fabry disease in Poland: a position statement[J]. Pol Arch Intern Med, 2020, 130(1): 91-97.
|
[11] |
王朝晖, 潘晓霞, 陈楠. 提高对法布里病临床表现和实验室新指标的认识[J]. 诊断学理论与实践, 2014, 13(1): 20-23. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDLS201401009.htm
|
[12] |
Favalli V, Disabella E, Molinaro M, et al. Genetic screening of Anderson-Fabry disease inprobands referred from multispecialty clinics[J]. J Am Coll Cardiol, 2016, 68(10): 1037-1050. doi: 10.1016/j.jacc.2016.05.090
|
[13] |
Mehta A, Clarke JT, Giugliani R, et al. Natural course of Fabry disease: changing pattern of causes of death in FOS-Fabry Outcome Survey[J]. J Med Genet, 2009, 46(8): 548-552. doi: 10.1136/jmg.2008.065904
|
[14] |
Yousef Z, Elliott PM, Cecchi F, et al. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis[J]. Eur Heart J, 2013, 34 (11): 802-808. doi: 10.1093/eurheartj/ehs166
|
[15] |
Nagueh SF. Fabry disease[J]. Heart, 2003, 89(8): 819-820. doi: 10.1136/heart.89.8.819
|
[16] |
Namdar M. Electrocardiographic changes and arrhythmia in Fabry disease[J]. Front Cardiovasc Med, 2016, 3: 7.
|
[17] |
Akhtar MM, Elliott PM. Anderson-Fabry disease in heart failure[J]. Biophys Rev, 2018, 10(4): 1107-1119. doi: 10.1007/s12551-018-0432-5
|
[18] |
El-Abassi R, Singhal D, England JD. Fabry's disease[J]. J Neurol Sci, 2014, 344(1-2): 5-19. doi: 10.1016/j.jns.2014.06.029
|
[19] |
Kampmann C, Wiethoff CM, Martin C, et al. Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy[J]. Acta Paediatr Suppl, 2002, 91(439): 21-27.
|
[20] |
Baig S, Vijapurapu R, Alharbi F, et al. Diagnosis and treatment of the cardiovascular consequences of Fabry disease[J]. QJM, 2019, 112(1): 3-9. doi: 10.1093/qjmed/hcy120
|
[21] |
Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients[J]. Mol Genet Metab, 2018, 123(4): 416-427. doi: 10.1016/j.ymgme.2018.02.014
|
[22] |
Tower-Rader A, Jaber WA. Multimodality imaging assess-ment of Fabry disease[J]. Circ Cardiovasc Imaging, 2019, 12(11): e009013. doi: 10.1161/CIRCIMAGING.119.009013
|
[23] |
Shanks M, Thompson RB, Paterson ID, et al. Systolic and diastolic function assessment in Fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements[J]. J Am Soc Echocardiogr, 2013, 26(12): 1407-1414. doi: 10.1016/j.echo.2013.09.005
|
[24] |
Krämer J, Niemann M, Liu D, et al. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease[J]. Eur Heart J, 2013, 34(21): 1587-1596. doi: 10.1093/eurheartj/eht098
|
[25] |
Perry R, Shah R, Saiedi M, et al. The role of cardiac imaging in the diagnosis and management of Anderson-Fabry Disease[J]. JACC Cardiovasc Imaging, 2019, 12(7Pt1): 1230-1242.
|
[26] |
Weidemann F, Beer M, Kralewski M, et al. Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study[J]. Mol Genet Metab, 2019, 126(2): 169-182. doi: 10.1016/j.ymgme.2018.11.005
|
[27] |
Hagège A, Réant P, Habib G, et al. Fabry disease in cardiology practice: literature review and expert point of view[J]. Arch Cardiovasc Dis, 2019, 112(4): 278-287. doi: 10.1016/j.acvd.2019.01.002
|
[28] |
Hanneman K, Karur GR, Wasim S, et al. Left ventricular hypertrophy and late gadolinium enhancement at cardiac MRI are associated with adverse cardiac events in Fabry disease[J]. Radiology, 2020, 294(1): 42-49. doi: 10.1148/radiol.2019191385
|
[29] |
Torralba-Cabeza MÁ, Olivera S, Hughes DA, et al. Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease[J]. Mol Genet Metab, 2011, 104(3): 301-307. doi: 10.1016/j.ymgme.2011.06.021
|
[30] |
Andrade J, Waters PJ, Singh RS, et al. Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test[J]. Clin J Am Soc Nephrol, 2008, 3(1): 139-145. doi: 10.2215/CJN.02490607
|
[31] |
Nakagawa N, Sawada J, Sakamoto N, et al. High-risk screening for Anderson-Fabry disease in patients with cardiac, renal, or neurological manifestations[J]. J Hum Genet, 2019, 64(9): 891-898. doi: 10.1038/s10038-019-0633-1
|
[32] |
Schiffmann R, Hughes DA, Linthorst GE, et al. Screen-ing, diagnosis, and management of patients with Fabry disease: conclusions from a " Kidney Disease: Improving Global Outcomes"(KDIGO) controversies conference[J]. Kidney Int, 2017, 91(2): 284-293. doi: 10.1016/j.kint.2016.10.004
|
[33] |
Sakuraba H, Togawa T, Tsukimura T, et al. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy[J]. Clin Exp Nephrol, 2018, 22(4): 843-849. doi: 10.1007/s10157-017-1525-3
|
[34] |
Politei J, Alberton V, Amoreo O, et al. Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?[J]. Pediatr Nephrol, 2018, 33(11): 2095-2101. doi: 10.1007/s00467-018-4006-3
|
[35] |
Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease[J]. Proc Natl Acad Sci U S A, 2008, 105(8): 2812-2817. doi: 10.1073/pnas.0712309105
|
[36] |
Auray-Blais C, Ntwari A, Clarke JT, et al. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?[J]. Clin Chim Acta, 2010, 411(23-24): 1906-1914. doi: 10.1016/j.cca.2010.07.038
|
[37] |
Nowak A, Mechtler T, Kasper DC, et al. Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease[J]. Mol Genet Metab, 2017, 121(4): 320-324. doi: 10.1016/j.ymgme.2017.06.006
|
[38] |
Cairns T, Müntze J, Gernert J, et al. Hot topics in Fabry disease[J]. Postgrad Med J, 2018, 94(1118): 709-713. doi: 10.1136/postgradmedj-2018-136056
|
[39] |
Sawada T, Kido J, Yoshida S, et al. Newborn screening for Fabry disease in the western region of Japan[J]. Mol Genet Metab Rep, 2020, 22: 100562.
|
[40] |
Hwu WL, Chien YH, Lee NC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c. 936+919G > A(IVS4+919G > A)[J]. Hum Mutat, 2009, 30(10): 1397-1405. doi: 10.1002/humu.21074
|
[41] |
Oder D, Liu D, Hu K, et al. α-Galactosidase A genotype N215S induces a specific cardiac variant of Fabry disease[J]. Circ Cardiovasc Genet, 2017, 10(5): e001691. doi: 10.1161/CIRCGENETICS.116.001691
|
[42] |
San Román-Monserrat I, Moreno-Flores V, López-Cuenca D, et al. Comprehensive clinical evaluation of a large Spanish family with Anderson-Fabry disease, novel GLA mutation and severe cardiac phenotype[J]. Med Clin (Barc), 2014, 142(11): 497-504. doi: 10.1016/j.medcli.2014.01.032
|
[43] |
Csányi B, Hategan L, Nagy V, et al. Identification of a novel GLA Gene mutation, p. Ile239Met, in Fabry disease with a predominant cardiac phenotype[J]. Int Heart J, 2017, 58 (3): 454-458. doi: 10.1536/ihj.16-361
|
[44] |
Linhart A, Germain DP, Olivotto I, et al. An expert consensus document on the management of cardiovascular manifestations of Fabry disease[J]. Eur J Heart Fail, 2020, 22(7): 1076-1096. doi: 10.1002/ejhf.1960
|
[45] |
Hsu TR, Chang FP, Chu TH, et al. Correlations between endomyocardial biopsies and cardiac manifestations in Taiwanese patients with the Chinese hotspot IVS4+919G > a mutation: data from the Fabry outcome survey[J]. Int J Mol Sci, 2017, 18(1): 119. doi: 10.3390/ijms18010119
|
[46] |
Weidemann F, Maier SK, Störk S, et al. Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in patients with advanced Fabry cardiomyopathy[J]. Am J Cardiol, 2016, 118(2): 264-274. doi: 10.1016/j.amjcard.2016.04.033
|
[47] |
Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. Eur Heart J, 2022, 43(40): 3997-4126. doi: 10.1093/eurheartj/ehac262
|
[48] |
Baig S, Edward NC, Kotecha D, et al. Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice[J]. Europace, 2018, 20(FI2): f153-f161. doi: 10.1093/europace/eux261
|
[49] |
Rob D, Marek J, Dostalova G, et al. Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations[J]. ESC Heart Fail, 2022, 9(6): 4043-4052. doi: 10.1002/ehf2.14091
|
[50] |
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2013, 62(16): e147-e239. doi: 10.1016/j.jacc.2013.05.019
|
[51] |
Bernardes TP, Foresto RD, Kirsztajn GM. Fabry disease: genetics, pathology, and treatment[J]. Rev Assoc Med Bras(1992), 2020, 66 Suppl 1(Suppl 1): s10-s16.
|
[52] |
Simonetta I, Tuttolomondo A, Daidone M, et al. Treat-ment of Anderson-Fabry Disease[J]. Curr Pharm Des, 2020, 26(40): 5089-5099. doi: 10.2174/1381612826666200317142412
|
[53] |
Caballero L, Climent V, Hernández-Romero D, et al. Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations[J]. Curr Med Chem, 2010, 17(16): 1679-1689. doi: 10.2174/092986710791111297
|
[54] |
Beck M, Hughes D, Kampmann C, et al. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis[J]. Mol Genet Metab Rep, 2015, 3: 21-27.
|
[55] |
Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment[J]. Orphanet J Rare Dis, 2015, 10: 125. doi: 10.1186/s13023-015-0338-2
|
[56] |
Gaggl M, Sunder-Plassmann G. Fabry disease: a pharmacological chaperone on the horizon[J]. Nat Rev Nephrol, 2016, 12 (11): 653-654. doi: 10.1038/nrneph.2016.138
|